Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1916 of 6351
-
Could your own muscle cells restore swallowing after cancer?
Disease control OngoingThe primary objective of this double-blind, randomized, placebo-controlled, multicenter clinical trial is to evaluate the safety of AMDC-GIR during the 24 months following 2 consecutive treatments of tongue dysphagia in male and female patients who have undergone surgery and/or c…
Phase 1/2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug aims to sharpen thinking in Huntington's patients
Symptom relief CompletedThe primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
Phase 2 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 26, 2026 17:02 UTC
-
Gentler Heart-Lung machine tested in 1,300-Patient trial
Disease control Recruiting nowMiECS is one of the largest multicentre randomised controlled trials on extracorporeal circulation conducted under the auspices of Minimal Invasive Extracorporeal Technologies International Society (MiECTiS). It is designed to ultimately address the emerging effectiveness of MiEC…
Sponsor: Aristotle University Of Thessaloniki • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Heart device showdown: could CCM beat CRT for chagas patients?
Disease control Recruiting nowChagas disease is an endemic problem in Latin America, where millions of people are chronically infected with T. cruzi. Recently, it was assumed to have clinical and epidemiological relevance in several other countries due to migratory and globalizing social factors. CCC occurs i…
Sponsor: InCor Heart Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental combo shows promise in tough sarcoma
Disease control CompletedThe purpose of this study is to asess the safety and tolerability and efficacy of LVGN6051 combined with anlotinib in patient with soft tissue sarcoma.
Phase 1/2 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Veterans' PTSD study seeks best treatment match
Symptom relief OngoingPosttraumatic Stress Disorder (PTSD) remains a salient and debilitating problem, in the general population and for military veterans in particular. Several psychological and pharmacological treatments for PTSD have evidence to support their efficacy. However, the lack of comparat…
Phase 4 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Brain scans train depressed minds to look away from negativity
Symptom relief CompletedThis study tests the efficacy of a new psychotherapeutic strategy for reducing negative attention bias (and therefore depression severity) in participants with MDD (60 in R61 phase and 80 in R33 Phase). This real-time fMRI neurofeedback therapy uses cloud-based pattern classifica…
Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jun 26, 2026 14:46 UTC
-
Experimental combo aims to boost chemo for tough blood cancers
Disease control Recruiting nowThis is a Phase 1b, open-label study evaluating Venetoclax in combination with intensive induction and consolidation chemotherapy in previously untreated, adult patients with acute myeloid leukemia. In Part 1, the dose escalation phase, the safety and tolerability of the combinat…
Phase 1 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug combo aims to control Hard-to-Treat myeloma
Disease control OngoingThe purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Glowing dye could help surgeons remove all cancer in one go
Diagnosis Recruiting nowIn this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Can a 14-Day Anti-Inflammatory shot stop heart failure after a heart attack?
Disease control OngoingPatients who have a heart attack are at high risk for future development of heart failure ('weakening of the heart'). The researchers believe that the reaction of the heart muscle to injury (inflammation) during a heart attack may be contributing to the risk of heart failure. The…
Phase 2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a smart scale and app tame childhood obesity?
Disease control Recruiting nowEvira is a digital support system newly developed for treatment of childhood obesity. Through daily weighings at home using a special scale together with a message function in the Evira application, enabling fast and easy communication with the clinic, parents and the clinicians …
Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Targeted pill shows promise for rare genetic cancers
Disease control CompletedThis study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of t…
Phase 2 • Sponsor: Endeavor Biomedicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Cholesterol control may cut stroke risk in brain artery disease
Disease control Recruiting nowsICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\>1.8mmol/L) without endovascular therapy.
Sponsor: Nanjing First Hospital, Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Your voice may reveal early dementia: new AI tool tested
Diagnosis CompletedMild Cognitive Impairment (MCI) is frequently underdiagnosed due to its subtle clinical presentation. This study evaluates the diagnostic performance of AcceXible, a speech analysis-based machine learning platform, compared to the Montreal Cognitive Assessment (MoCA) for MCI dete…
Sponsor: Accexible • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
500 stroke patients enrolled to uncover hidden clues in blood and brain scans
Knowledge-focused Recruiting nowIschemic stroke is the first cause of acquired disability of the adult, the second cause of dementia and the third cause of death in the industrialized countries, what constitutes à major public health issue. Stroke is characterized by a cerebral parenchymal lesion due to an isch…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New hope for leukemia patients Who've run out of options
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TK…
Phase 1 • Sponsor: Enliven Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug candidate BL-M02D1 enters human trials for Hard-to-Treat cancers
Disease control OngoingIn phase Ia study, the safety and tolerability of BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M02D1. In phase I…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Smart bracelets could read the hidden signs of apathy in dementia
Knowledge-focused CompletedECOCAPTURE@HOME is a study which is currently being developed with the objective to capture the behavioral signature of apathy in everyday life context through remote monitoring of participants' behavior for about one month. Participants will not only be patients with apathy but …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
A brainstem dose limit might spare brain tumor patients from radiation nausea
Knowledge-focused CompletedPatients irradiated to the brain frequently experience nausea. The dorsal vagal complex (DVC) area is a specific brainstem zone and has been identified as likely responsible for nausea. Existing clinical studies show correlation between dose to the DVC and nausea, but they concer…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC